POSCO Stock Slides As Lithium Slump Spurs Fresh Fears
Rocket Lab (RKLB) shares fell 11% on Thursday, extending monthly losses to 25%, after delaying its Neutron rocket's inaugural flight to 2027 due to a manufacturing defect. Analyst Suji Desilva maintains a Buy rating and $110 price target, citing long-term benefits of the delay. Wall Street consensus remains bullish with a Strong Buy rating and $100.75 average price target.
How this was made
The 30-second read
Why it matters
A specific manufacturing defect (air pockets in carbon-fiber propellant tank dome) forces a process change and extends the inaugural flight to 2027, increasing schedule uncertainty while leaving near-term revenue assumptions unchanged per the cited analyst.
Market read
Traders get a concrete catalyst: Neutron’s first flight pushed to 2027, plus a countervailing analyst thesis that forecasts need not change.
What to watch
The article notes Neutron revenue is excluded from current forecasts, so the market may be trading expectations and optionality rather than near-term financials; watch for updated milestone dates after replacement dome completion.
Background
The article frames Neutron as Rocket Lab’s medium-lift expansion beyond Electron, with investors focused on the inaugural flight timeline.
Ticker impact
Rocket Lab shares fall after Neutron’s inaugural flight slips to 2027 due to a manufacturing defect in the first-stage propellant tank dome.
Likely near-term pressure as investors reprice Neutron timing risk, partially offset by bullish analyst reiteration and unchanged estimates.
The piece reports a concrete program slip to 2027 tied to a specific manufacturing defect and mitigation plan, which typically weighs on launch-dependent valuation, even with a supportive Buy thesis.
Market effects
Highlights ongoing execution and manufacturing reliability challenges in the commercial space launch sector, which can pressure sentiment across launch names.
Primarily US-listed small/mid-cap growth sentiment, with potential spillover to other space and aerospace suppliers.
Limited direct global macro linkage, but reinforces global investor focus on launch cadence and manufacturing quality.
Counterpoint
The delay may reduce execution risk by shifting to automated fiber placement and replacing supplier processes, potentially improving first-flight success odds.
Key entities
- companyRocket Lab
US-listed launch provider whose Neutron program is delayed to 2027 due to a manufacturing defect and mitigation plan.
- analyst_firmRoth Capital
Cited as maintaining a Buy rating and $110 price target despite the setback.
- analystSuji Desilva
Roth Capital analyst who reiterates Buy and argues reliability-focused manufacturing changes have benefits.
